“ Our direction is consistent and disciplined: deliver on the AI agenda, reinforce prevention-focused infrastructure and scale our capabilities internationally through structured partnerships. ”
Featured Content
2026 could mark a turning point for biosimilar adoption in the US. By scrapping requirements for redundant clinical trials and pushing Congress to end the “Interchangeable” label, the FDA has cleared the runway for biosimilars. However, with PBM “rebate walls” and patent thickets still standing, will these lower cost therapies finally take off in the…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft for a new BIOSECURE Act. While the final version of the law, signed by President Donald Trump in December 2025, was softer than the…
France’s healthcare and life sciences sector enters 2026 with cautious momentum. With the annual budget finally making its way through the French parliament, stakeholders can look forward to the year ahead in Europe’s second-largest market with increased certainty. And, as this exclusive new report shows, there is plenty to be optimistic about. Healthcare & Life…
In Conversation
Kim Moran – SVP & Head of US Rare Disease, UCB
“ In many ways, our move into rare disease is a natural extension of our deep expertise in neurological science ”
Neil Archer – EVP International, Madrigal
“ We achieved what 24 companies before us could not – the first approved treatment for MASH. ”
Kenichi Nakamura – Director, Department of International Clinical Development, National Cancer Center Hospital, Japan
“ Our priority is to strengthen Asia’s role in both the development and the delivery of innovative therapies ”
Marco Billi – International CEO, Eurofarma
“ Latin America has always been a challenging region, marked by regulatory fragmentation, currency volatility, and frequent policy shifts. ”
Sabrina Chan – Senior Executive, HKAPI
“ Hong Kong's Centre for Medical Products Regulation is planned to conduct its first primary review within this year. This represents rapid movement from concept to implementation ”
Inside Ipsen's Home Market Strategy
“ It is both energising and meaningful to serve Ipsen's home market ”
Chen-Yu Cheng – Founder & Chairman, Formosa Group
“ To be successful, you cannot just "do the right thing" – you must be bold enough to take calculated risks ”
Rania Alshami – Chief Business and Strategy Officer, PDC-CRO
“ The burden of rare disease in the region is substantial. We are speaking about a rare patient population of approximately 25 million, comparable to the US and Europe, with a high incidence of metabolic, haematological, and neurological diseases ”
